Biocept Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Rhea-AI Summary

Biocept, Inc. (NASDAQ: BIOC) has granted inducement stock options to 44 new employees, totaling 519,140 shares. Notably, Chief Operations Officer Philippe Marchand received an option for 150,000 shares. These options have a grant date of March 31, 2022, with an exercise price of $2.32 per share, equal to the stock's closing price on that date. The options vest over four years, aligning with Nasdaq Listing Rule 5635(c)(4). Biocept specializes in molecular diagnostic assays for cancer treatment and monitoring, further expanding its workforce to enhance its operational capacity.

Positive

• Inducement stock options granted to 44 new employees, indicating company growth.
• Philippe Marchand appointed as COO, likely to bolster operational leadership.

Negative

• None.

SAN DIEGO--(BUSINESS WIRE)-- Biocept, Inc. (Nasdaq: BIOC), a leading provider of molecular diagnostic assays, products and services, today announced that it has granted inducement stock options to purchase an aggregate of 519,140 shares of its common stock to 44 new employees, including an inducement stock option to purchase 150,000 shares of its common stock to Philippe Marchand, Ph.D., its new Chief Operations Officer. The inducement stock options have a grant date of March 31, 2022, and were granted as inducements material to the new employees entering into employment with Biocept in accordance with Nasdaq Listing Rule 5635(c)(4).

The inducement stock options have an exercise price of $2.32 per share, the closing price of Biocept’s common stock on March 31, 2022, are non-qualified stock options, have a ten-year term and vest over four years, with 25% of the shares vesting on the one-year anniversary of the vesting commencement date and the remaining 75% of the shares vesting in equal monthly installments over the following 36 months, subject to the new employees’ continued service with Biocept through the applicable vesting dates. The inducement stock options are subject to the terms and conditions of Biocept’s Amended and Restated 2013 Equity Incentive Plan, as amended.

About Biocept

Biocept, Inc. develops and commercializes molecular diagnostic assays that provide physicians with clinically actionable information for treating and monitoring patients diagnosed with a variety of cancers. In addition to its broad portfolio of blood-based liquid biopsy assays, Biocept has developed the CNSide™ cerebrospinal fluid assay that detects cancer that has metastasized to the central nervous system. Biocept’s patented Target Selector™ technology captures and quantitatively analyzes cerebrospinal fluid tumor cells for tumor-associated molecular markers, using technology first developed for use in blood. Biocept also is leveraging its molecular diagnostic capabilities to offer nationwide COVID-19 RT-PCR testing to support public health efforts during this unprecedented pandemic. For more information, visit www.biocept.com. Follow Biocept on Facebook, LinkedIn and Twitter.

Forward-Looking Statements Disclaimer

This release contains forward-looking statements that are based upon current expectations or beliefs, as well as a number of assumptions about future events. Although Biocept believes that the expectations reflected in the forward-looking statements and the assumptions upon which they are based are reasonable, Biocept can give no assurance that such expectations and assumptions will prove to have been correct. Forward-looking statements are generally identifiable by the use of words like “may,” “will,” “could,” “expect,” or “believe” or the negative of these words or other variations on these words or comparable terminology. To the extent that statements in this release are not strictly historical, including without limitation statements regarding the capabilities and potential benefits of Biocept’s CNSide assay and the ability of Biocept’s assays to provide physicians with clinically actional information, such statements are forward-looking, and are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. The reader is cautioned not to put undue reliance on these forward-looking statements, as these statements are subject to numerous risks and uncertainties, including the risk that Biocept’s products and services may not perform as expected. These and other risks are described in greater detail under the “Risk Factors” heading of Biocept’s Annual Report on Form 10-K for the year ended December 31, 2021, filed with the Securities and Exchange Commission (SEC) on April 5, 2022. The effects of such risks and uncertainties could cause Biocept’s actual results to differ materially from the forward-looking statements contained in this release. Biocept does not plan to update any such forward-looking statements and expressly disclaims any duty to update the information contained in this press release except as required by law. Readers are advised to review Biocept’s filings with the SEC, which can be accessed over the Internet at the SEC’s website located at www.sec.gov.

View source version on businesswire.com: https://www.businesswire.com/news/home/20220408005449/en/

Investor Contact:

Jody Cain, LHA Investor Relations

Jcain@lhai.com, 310-691-7100

Media Contact:

Andrea Sampson, Sampson PR Group

asampson@sampsonprgroup.com, 562-304-0301

Source: Biocept, Inc.

FAQ

What are the details of the employee stock options announced by Biocept?

Biocept announced inducement stock options for 44 new employees, totaling 519,140 shares, with an exercise price of $2.32 per share.

When were the inducement stock options granted by Biocept?

The inducement stock options were granted on March 31, 2022.

Who is the new COO of Biocept?

Philippe Marchand, Ph.D., has been appointed as the new Chief Operations Officer of Biocept.